secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001601830-22-000034
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Recursion reports Q3 net loss of $60.4M, initiates two clinical trials; raises $150M private placement
--------------------------------------------------------------------------------

- Cash and cash equivalents $454.6M as of Sept 30, 2022; excludes $150.3M private placement closed Oct 27.
- Revenue $13.2M (up from $2.5M YoY) on Roche-Genentech collaboration; net loss $60.4M vs $47.4M YoY.
- Initiated Phase 2 TUPELO trial for REC-4881 in FAP and Phase 1 trial for REC-3964 in C. diff colitis.
- Nominated REC-4881 for AXIN1/APC mutant cancers; planning Phase 2 trial; deprioritized GM2 gangliosidosis.
- R&D expenses $40.8M, G&A $19.5M; both increased due to clinical progress and company growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183022000034/0001601830-22-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183022000034/rxrx-20221108.htm
  HTML page:      https://secwatch.observer/filing/0001601830-22-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer